CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...